Research programme: pellino inhibitors - Atomwise/Bridge Biotherapeutics
Latest Information Update: 28 Apr 2024
At a glance
- Originator Atomwise; Bridge Biotherapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Ubiquitin protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Inflammation in South Korea
- 28 Apr 2024 No recent reports of development identified for research development in Inflammation in USA
- 09 Mar 2020 Bridge Biotherapeutics and Atomwise collaborate to develop small molecule pellino inhibitors